Lv2
180 积分 2025-03-23 加入
Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents
13小时前
待确认
[Hormone stimulation of rooting]
2天前
已关闭
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
8天前
已完结
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
17天前
已完结
TYK2: an emerging therapeutic target in rheumatic disease
17天前
已完结
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
17天前
已完结
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
17天前
已完结
Epidemiology of Onychomycosis in Chinese Mainland: A 30-year Retrospective Study
18天前
已完结
Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents
1个月前
已完结
Oteseconazole: First Approval
1个月前
已完结
皖公网安备34019202002308
